Neuberg Diagnostics, a leading player in India’s diagnostic sector, recently secured a major investment of ₹940 crore from Kotak Strategic Situations India Fund II. This investment, aimed at supporting Neuberg’s expansion strategy, is expected to play a crucial role in the company’s growth plans.
Founded by industry veteran GSK Velu, Neuberg Diagnostics operates a vast network of over 10,000 touchpoints and 250 labs across 250 cities in India. The company has established market leadership in states like Gujarat and Karnataka. In addition to its diagnostic services, Neuberg is also noted as the second-largest genomics player in India, with expertise in newborn screening and reproductive genomics testing.
Rahul Shah, Partner at Kotak Alt, expressed confidence in Neuberg’s growth potential and highlighted that the investment would support the company’s scaling efforts and prepare it for an upcoming IPO. GSK Velu, the Founder and MD of Neuberg, stated that the investment would enhance the company’s capabilities in personalized medicine, integrated diagnostics, and fuel its inorganic growth across India.
As Neuberg prepares for an IPO, the company remains committed to making high-quality diagnostics accessible to all. The significant investment from Kotak Strategic Situations India Fund II is a testament to Neuberg’s strong position in the market and its potential for further growth and innovation in the healthcare sector.
